Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in shape enough to tolerate FCR therapy, should be superior candidates for that latter, Along with the reward becoming this cure could be finished in six months even though ibrutinib should be taken indefinitely. This selection would be notably important for non-compliant ind